Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens

M. Kuriyama, M. C. Wang, C. L. Lee, C. S. Killian, L. D. Papsidero, H. Inaji, R. M. Loor, M. F. Lin, T. Nishiura, N. H. Slack, G. P. Murphy, T. M. Chu

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Serum prostate-specific antigen and prostatic acid phosphatase were simultaneously evaluated in 22 healthy males, 29 patients with benign prostatic hypertrophy, and 192 patients with prostate cancers at various stages as well as in 30 patients with cancers other than prostate cancer. Both markers were quantitated by specific sandwich-type, enzyme-linked, immunosorbent assays with the use of specific antiserum reagents. Serum assays revealed a discordance between these two markers; thus expressions of these two biochemically and immunologically distinct prostate-specific proteins may reflect different aspects in the biology of prostate cancer. A combination test with the use of 7.5 ng of prostate antigen and 15.5 ng of prostatic acid phosphatase/ml of serum, respectively, as cutoff values resulted in a positive detection rate of 58% for prostate cancers of stages A (7/12) and B (21/36) each, 68% for prostate cancer of stage C (19/28), 92% for prostate cancer of stage D (106/116), and only 10% for benign prostatic hypertrophy (3/29). None of 52 other cancers or healthy controls was registered as positive. This study demonstrates that a multiple marker test of tissue-specific antigens can be of an additive value in the immunodiagnosis of cancer and may be a logical and effective approach at this time, in light of the unavailability of human tumor-specific markers.

Original languageEnglish (US)
Pages (from-to)99-105
Number of pages7
JournalJournal of the National Cancer Institute
Volume68
Issue number1
StatePublished - Apr 5 1982

Fingerprint

Prostatic Neoplasms
Antigens
Prostatic Hyperplasia
Prostate
Serum
Immunologic Tests
Prostate-Specific Antigen
Tumor Biomarkers
Immune Sera
Neoplasms
Enzyme-Linked Immunosorbent Assay
Proteins

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kuriyama, M., Wang, M. C., Lee, C. L., Killian, C. S., Papsidero, L. D., Inaji, H., ... Chu, T. M. (1982). Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens. Journal of the National Cancer Institute, 68(1), 99-105.

Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens. / Kuriyama, M.; Wang, M. C.; Lee, C. L.; Killian, C. S.; Papsidero, L. D.; Inaji, H.; Loor, R. M.; Lin, M. F.; Nishiura, T.; Slack, N. H.; Murphy, G. P.; Chu, T. M.

In: Journal of the National Cancer Institute, Vol. 68, No. 1, 05.04.1982, p. 99-105.

Research output: Contribution to journalArticle

Kuriyama, M, Wang, MC, Lee, CL, Killian, CS, Papsidero, LD, Inaji, H, Loor, RM, Lin, MF, Nishiura, T, Slack, NH, Murphy, GP & Chu, TM 1982, 'Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens', Journal of the National Cancer Institute, vol. 68, no. 1, pp. 99-105.
Kuriyama M, Wang MC, Lee CL, Killian CS, Papsidero LD, Inaji H et al. Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens. Journal of the National Cancer Institute. 1982 Apr 5;68(1):99-105.
Kuriyama, M. ; Wang, M. C. ; Lee, C. L. ; Killian, C. S. ; Papsidero, L. D. ; Inaji, H. ; Loor, R. M. ; Lin, M. F. ; Nishiura, T. ; Slack, N. H. ; Murphy, G. P. ; Chu, T. M. / Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens. In: Journal of the National Cancer Institute. 1982 ; Vol. 68, No. 1. pp. 99-105.
@article{33232763eb9c4fb1a4100e0aaebbfc2a,
title = "Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens",
abstract = "Serum prostate-specific antigen and prostatic acid phosphatase were simultaneously evaluated in 22 healthy males, 29 patients with benign prostatic hypertrophy, and 192 patients with prostate cancers at various stages as well as in 30 patients with cancers other than prostate cancer. Both markers were quantitated by specific sandwich-type, enzyme-linked, immunosorbent assays with the use of specific antiserum reagents. Serum assays revealed a discordance between these two markers; thus expressions of these two biochemically and immunologically distinct prostate-specific proteins may reflect different aspects in the biology of prostate cancer. A combination test with the use of 7.5 ng of prostate antigen and 15.5 ng of prostatic acid phosphatase/ml of serum, respectively, as cutoff values resulted in a positive detection rate of 58{\%} for prostate cancers of stages A (7/12) and B (21/36) each, 68{\%} for prostate cancer of stage C (19/28), 92{\%} for prostate cancer of stage D (106/116), and only 10{\%} for benign prostatic hypertrophy (3/29). None of 52 other cancers or healthy controls was registered as positive. This study demonstrates that a multiple marker test of tissue-specific antigens can be of an additive value in the immunodiagnosis of cancer and may be a logical and effective approach at this time, in light of the unavailability of human tumor-specific markers.",
author = "M. Kuriyama and Wang, {M. C.} and Lee, {C. L.} and Killian, {C. S.} and Papsidero, {L. D.} and H. Inaji and Loor, {R. M.} and Lin, {M. F.} and T. Nishiura and Slack, {N. H.} and Murphy, {G. P.} and Chu, {T. M.}",
year = "1982",
month = "4",
day = "5",
language = "English (US)",
volume = "68",
pages = "99--105",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens

AU - Kuriyama, M.

AU - Wang, M. C.

AU - Lee, C. L.

AU - Killian, C. S.

AU - Papsidero, L. D.

AU - Inaji, H.

AU - Loor, R. M.

AU - Lin, M. F.

AU - Nishiura, T.

AU - Slack, N. H.

AU - Murphy, G. P.

AU - Chu, T. M.

PY - 1982/4/5

Y1 - 1982/4/5

N2 - Serum prostate-specific antigen and prostatic acid phosphatase were simultaneously evaluated in 22 healthy males, 29 patients with benign prostatic hypertrophy, and 192 patients with prostate cancers at various stages as well as in 30 patients with cancers other than prostate cancer. Both markers were quantitated by specific sandwich-type, enzyme-linked, immunosorbent assays with the use of specific antiserum reagents. Serum assays revealed a discordance between these two markers; thus expressions of these two biochemically and immunologically distinct prostate-specific proteins may reflect different aspects in the biology of prostate cancer. A combination test with the use of 7.5 ng of prostate antigen and 15.5 ng of prostatic acid phosphatase/ml of serum, respectively, as cutoff values resulted in a positive detection rate of 58% for prostate cancers of stages A (7/12) and B (21/36) each, 68% for prostate cancer of stage C (19/28), 92% for prostate cancer of stage D (106/116), and only 10% for benign prostatic hypertrophy (3/29). None of 52 other cancers or healthy controls was registered as positive. This study demonstrates that a multiple marker test of tissue-specific antigens can be of an additive value in the immunodiagnosis of cancer and may be a logical and effective approach at this time, in light of the unavailability of human tumor-specific markers.

AB - Serum prostate-specific antigen and prostatic acid phosphatase were simultaneously evaluated in 22 healthy males, 29 patients with benign prostatic hypertrophy, and 192 patients with prostate cancers at various stages as well as in 30 patients with cancers other than prostate cancer. Both markers were quantitated by specific sandwich-type, enzyme-linked, immunosorbent assays with the use of specific antiserum reagents. Serum assays revealed a discordance between these two markers; thus expressions of these two biochemically and immunologically distinct prostate-specific proteins may reflect different aspects in the biology of prostate cancer. A combination test with the use of 7.5 ng of prostate antigen and 15.5 ng of prostatic acid phosphatase/ml of serum, respectively, as cutoff values resulted in a positive detection rate of 58% for prostate cancers of stages A (7/12) and B (21/36) each, 68% for prostate cancer of stage C (19/28), 92% for prostate cancer of stage D (106/116), and only 10% for benign prostatic hypertrophy (3/29). None of 52 other cancers or healthy controls was registered as positive. This study demonstrates that a multiple marker test of tissue-specific antigens can be of an additive value in the immunodiagnosis of cancer and may be a logical and effective approach at this time, in light of the unavailability of human tumor-specific markers.

UR - http://www.scopus.com/inward/record.url?scp=0020034944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020034944&partnerID=8YFLogxK

M3 - Article

C2 - 6172628

AN - SCOPUS:0020034944

VL - 68

SP - 99

EP - 105

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 1

ER -